Although potent AR pathway inhibitors (ARPIs), such as enzalutamide, abiraterone acetate and apalutamide, have therapeutic effects on CRPC, these tumors almost inevitably develop AR-independent pathways to sustain tumor growth after the long-term usage of ARPIs [4,5]. Here, AR is linked to neoplasm.